Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Application of Differentiation to Business01:29

Application of Differentiation to Business

280
Calculus offers essential techniques for businesses seeking to optimize pricing strategies and revenue. In this case, a bakery wants to determine the ideal price and daily sales volume to maximize revenue. By modeling how changes in price affect demand and revenue, the bakery can apply calculus to make data-driven decisions.The demand function relates the price per cupcake to the number of cupcakes sold and captures how lower prices increase sales. Based on market data, the demand function can...
280
Decision Making: P-value Method01:09

Decision Making: P-value Method

7.1K
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can...
7.1K
Applications of Integration to Find Consumer Surplus01:29

Applications of Integration to Find Consumer Surplus

83
In microeconomics, consumer surplus represents the economic gain that consumers experience when they purchase a good or service for less than the highest price they are willing to pay. This surplus arises from the characteristics of the demand function, which links the quantity of a good to the price consumers are willing to pay. As the quantity of a good increases, the price that consumers are willing to pay for each additional unit typically decreases, resulting in a downward-sloping demand...
83
Health Information Technology and Healthcare Information System01:30

Health Information Technology and Healthcare Information System

3.6K
Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
3.6K
Creative Thinking01:25

Creative Thinking

1.4K
Creative thinking encompasses innovative and unconventional methods for addressing challenges, often leading to groundbreaking solutions. Instead of focusing solely on enhancing existing systems, such as increasing smartphone battery capacity, creative thinking might inspire advancements like energy-efficient batteries or processors that minimize power consumption. This multidimensional approach underscores the importance of exploring novel pathways to innovation.
Divergent thinking is the...
1.4K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

348
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
348

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient-reported outcomes for hidradenitis suppurativa.

The British journal of dermatology·2025
Same author

Evaluating the Appropriateness of Existing Health-Related Quality of Life Measures in Lichen Planus.

Dermatology and therapy·2023
Same author

Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials.

Journal of the American Academy of Dermatology·2023
Same author

Patient Experience of Lichen Planus: A Qualitative Exploration of Signs, Symptoms, and Health-Related Quality of Life Impacts.

Dermatology and therapy·2023
Same author

The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework.

Journal of market access & health policy·2019
Same author

Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review.

Expert review of pharmacoeconomics & outcomes research·2016

Related Experiment Video

Updated: Mar 22, 2026

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups
14:14

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups

Published on: May 13, 2022

6.4K

The value of innovation under value-based pricing.

Santiago G Moreno1, Joshua A Ray1

  • 1Global Pricing and Market Access Department, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Journal of Market Access & Health Policy
|April 29, 2016
PubMed
Summary

Cost-effectiveness analysis (CEA) underestimates innovative drug value. A modified CEA incorporating future patient benefits and off-patent prices can better incentivize drug innovation while ensuring healthcare sustainability.

Keywords:
cost-effectiveness analysisdynamic cost-effectiveness analysisinnovationvalue-based pricing

More Related Videos

Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights
05:26

Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights

Published on: October 25, 2024

1.9K
Studying Food Reward and Motivation in Humans
12:09

Studying Food Reward and Motivation in Humans

Published on: March 19, 2014

24.3K

Related Experiment Videos

Last Updated: Mar 22, 2026

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups
14:14

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups

Published on: May 13, 2022

6.4K
Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights
05:26

Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights

Published on: October 25, 2024

1.9K
Studying Food Reward and Motivation in Humans
12:09

Studying Food Reward and Motivation in Humans

Published on: March 19, 2014

24.3K

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Drug Pricing

Background:

  • The conventional cost-effectiveness analysis (CEA) framework is debated for its role in incentivizing pharmaceutical innovation.
  • Critics argue CEA undervalues the 'value of innovation' by not fully accounting for long-term benefits and future savings.
  • Supporters contend that existing CEA methods already incorporate the value of innovation.

Purpose of the Study:

  • To identify the limitations of the conventional CEA approach in evaluating innovative drugs.
  • To propose an alternative CEA methodology that more accurately captures the total lifetime value of innovation.
  • To address the controversy surrounding CEA's impact on drug development incentives.

Main Methods:

  • The study identifies two key omissions in conventional CEA: benefits to future patient populations and future cost savings from off-patent prices.
  • A modified CEA approach is proposed that incorporates these elements to calculate the total lifetime value of an innovative drug.
  • The alternative approach suggests negotiating the share of the value of innovation between manufacturers and payers to determine drug pricing.

Main Results:

  • Conventional CEA underestimates the value of innovative drugs, leading to underpricing and manufacturers capturing only ~15% of the innovation value during patent periods.
  • The proposed CEA method, by including incidence patients and off-patent prices, derives a more accurate total lifetime value.
  • The alternative approach facilitates pricing negotiations to ensure manufacturers capture a greater share (>15%) of the innovation value.

Conclusions:

  • Modifying CEA to include the total lifetime value of innovative drugs, considering off-patent pricing and future patient benefits, is advocated.
  • This revised approach can incentivize innovation by allowing manufacturers to capture a fair share of value while supporting allocative efficiency in healthcare.
  • Policy makers should assess the long-term sustainability of healthcare systems before adopting the proposed CEA modifications.